Person: Portero Fuentes, Miriam
Loading...
First Name
Miriam
Last Name
Portero Fuentes
Affiliation
Universidad Complutense de Madrid
Faculty / Institute
Department
Area
Identifiers
7 results
Search Results
Now showing 1 - 7 of 7
Item Efficacy of Medical Ozone as an Adjuvant Treatment in Dogs with Intervertebral Disc Protusions: A Retrospective Study(Animals, 2023) Portero Fuentes, Miriam; Villalonga Rodríguez, Luis; Hernández, Mercedes; Pérez Díaz, CarmenOzone-therapy is used in humans as a coadjutant treatment in intervertebral disc diseases due to its analgesic, anti-inflammatory and antioxidant effects. References in dogs are scarce and limited to clinical cases (intradiscal/paravertebral infiltrations). The aim of this study was to assess the use of medical ozone (MO) as an adjunctive treatment in dogs with intervertebral disc protrusions (Hansen Type II/Chronic). A retrospective study was conducted in dogs diagnosed with intervertebral disc protrusions by MRI/CT in which MO was used as an adjuvant therapy to conventional medical treatment. Neurological examination and quality of life (QL) at the beginning and end of study were recorded, as well as posology and possible side effects. A total of 21 patients of different breeds and sex with a mean age of 12 years were included in this study. Results showed pain relief (7 ± 3 days) and improvement of neurologic signs (11 ± 9 days) with a consequent increasement in QL (13 ± 9 days). Thirteen out of the twenty-one patients (62%) showed a complete remission of the clinical signs. No serious adverse effects were observed. Medical ozone could be a potential complementary therapy to medical treatment in dogs with intervertebral disc protrusions. Prospective studies are necessary.- Project number: 289
Item Virtualización e impresión 3D de modelos anatómicos aplicados a la docencia y planificación quirúrgica IV(2021) Pérez Díaz, Carmen; Rodríguez Quirós, Jesús; De La Morena García, Eva; Portero Fuentes, Miriam; Gaspar Simón, Ignacio de; Villar de Gracia, Ana; Taberneiro Auiget, Daniel; Aranzana Enriquez, Daniel; Bernardi Villavicencio, Cristina Item Active surveillance of antimicrobial resistance in companion animals: A pilot study in a Spanish Veterinary Teaching Hospital(Comparative Immunology, Microbiology and Infectious Diseases, 2024) Scarpellini, Raffaele; Leal Vélez de Mendizábal, Laura; Quevedo Caraballo, Sergio; Blanco Cancelo, José Luis; García Sánchez, Marta Eulalia; Pérez Sancho, Marta; Portero Fuentes, Miriam; Penelo Hidalgo, Silvia; Esposito, Erika; Mondo, Elisabetta; Piva, SilviaThe role of small animal veterinary hospitals in the onset and dissemination of antimicrobial-resistant organisms (AMROs) is still not clear, and the implementation of an internal surveillance systems is a cost-effective tool to better understand their impact. The aim of this study was to describe a pilot program of active surveillance in a Spanish Veterinary Teaching Hospital, developed to estimate the detection frequency of AMROs in the commensal flora of patients and in the environment. Surveillance was focused on Methicillin-resistant Staphylococci (MRS), third generation cephalosporins resistant gram-negative bacteria (3GCR-GNB), and carbapenems-resistant gram-negative bacteria (CR-GNB). Oral and perirectal swabs were collected in the same dogs and cats hospitalized > 48 h, at their admission and before their discharge. Out of 50 patients sampled, 24% (12/50) were carriers at admission of at least one of the three investigated AMROs. Twenty-eight percent of patients (14/50) acquired at least one AMRO during the hospital stay. MRS detection frequency at admission was 12% (6/50), while acquisition was 6% (3/50). 3GCR-GNB detection frequency was 14% at admission (7/50) and acquisition 22% (11/50), while CR-GNB detection frequency was 2% at admission (1/50) and acquisition 2% (1/50). Environmental surveillance (98 samples) showed a total detection frequency of 22.4% for MRS (22/98), 2% for 3GCR-GNB and CR-GNB (2/98). Clinical staff’ shoe soles showed high detection frequency for MRS (50%). 3GCR Escherichia coli was the most isolated species in patients (n = 17). The results show how active surveillance can be used as a tool to assess the impact of AMROs in veterinary hospitals to subsequently build up tailored control plans based on specific issues.Item Survival of dogs with pituitary‐dependent hyperadrenocorticism treated twice daily with low doses of trilostane(Veterinary Record, 2022) García San José, Paula; Arenas Bermejo, Carolina; Alonso Miguel, Daniel; González Sanz, Sandra; Clares Moral, Irene; Portero Fuentes, Miriam; Pérez Alenza, María De Los DoloresBackground Twice daily low trilostane doses have proven to be effective to manage canine Cushing's syndrome. However, survival and prognostic factors in dogs treated with this protocol have not been evaluated. The aim of the study was to evaluate survival and prognostic factors, including systolic blood pressure (SBP) at diagnosis, in dogs with pituitary-dependent hypercortisolism (PDH) treated with low trilostane doses. Methods Medical records of 91 dogs newly diagnosed with PDH initially treated with 0.2–1.1 mg/kg of trilostane twice daily were retrospectively included. Survival times were calculated using the Kaplan–Meier estimator. Univariable and multivariable analysis were performed using the Cox proportional hazard regression analysis. Results Overall, median survival was 998 days (range 26–1832 days, 95% confidence interval = 755–1241 days). In the multivariable analysis, age (hazard ratio [HR] = 1.337, p < 0.001), presence of calcinosis cutis (HR = 5.271, p < 0.001), body condition score (BCS) ≤3/9 (HR = 8.100, p < 0.001) and higher platelet count (HR = 1.002, p = 0.022) were negatively correlated with survival. SBP was not associated with survival. Conclusions Low-dose trilostane treatment twice daily provides slightly longer survival than previously reported for dogs with PDH treated once or twice daily at higher doses. Older age, presence of calcinosis cutis, low BCS and higher platelet count, but not systemic hypertension, are predictive of poorer prognosis in dogs with PDH.Item Clinical signs, diagnostic imaging and histopathology in a dog with granulomatous meningoencephalitis manifested as a polyneuropathy(Veterinary Record Case Reports, 2022) Benito Benito, Miguel; Portero Fuentes, Miriam; Manso Díaz, Gabriel; Sánchez Madonado, Belén; Pérez Díaz, CarmenAn 11-year-old, female, neutered labrador retriever with a history of chronic and progressive right hindlimb lameness and facial asymmetry was referred for brain and lumbosacral magnetic resonance imaging and cerebrospinal fluid analysis. Multifocal non-enhancing T2-weighted images of hyperintense lesions were observed in the caudate nuclei and medulla oblongata. The right oculomotor nerve was markedly enlarged and showed marked enhancement on T1-weighted images after contrast injection, and there was diffuse enlargement of the sciatic and femoral nerves in the right hindlimb. Cerebrospinal fluid analysis showed a mixed pleocytosis. Histopathology revealed granulomatous inflammation affecting the brain, oculomotor and pelvic limb nerves, consistent with a diagnosis of granulomatous meningoencephalomyelitis.- Project number: 282
Item Virtualización e impresión 3D de modelos anatómicos aplicados a la docencia en Anatomía y Cirugía Veterinaria III(2020) Pérez Díaz, Carmen; Gaspar Simón, Ignacio de; Rodríguez Quirós, Jesús; Villalonga Rodríguez, Luis; Portero Fuentes, Miriam; Bernardi Villavicencio, Cristina; Morena García, Eva de la; Hernández De Frutos, Sandra; Labrador Pérez, Ángela; García Pérez, EnriqueCreación y aplicación de modelos anatómicos en 3D en la docencia de asignaturas de anatomía y cirugía en el grado de veterinaria Item Clinical outcome of dogs diagnosed with canine inflammatory mammary cancer treated with metronomic cyclophosphamide, a cyclooxygenase‐2 inhibitor and toceranib phosphate(Veterinary and Comparative Oncology, 2022) Alonso Miguel, Daniel; Valdivia Lara, Edgar Guillermo; García San José, Paula; Alonso Díez, Ángela; Clares, Irene; Portero Fuentes, Miriam; Peña Fernández, Laura Luisa; Pérez Alenza, María De Los DoloresCanine inflammatory mammary cancer (IMC) is highly malignant, invasive and a therapeutic challenge, because effective medical treatment is still unavailable. This retrospective study compares the efficacy of an oral cyclooxygenase-2 (COX-2) inhibitor combined with toceranib phosphate and oral cyclophosphamide (multi-drug therapy [MT]) with COX-2 inhibitor therapy alone (single-drug therapy [ST]) in dogs diagnosed with secondary IMC. Clinical response, adverse events, overall survival time (OST), disease-free survival (DFS) and time to progression (TTP) were evaluated. Sixteen patients were included, eight received MT and eight receiving ST. Median OST was significantly higher in patients receiving MT (96.0 vs. 37.5 days; p = .046) and in patients with post-surgical rather than non-surgical IMC (86.5 vs. 41.5 days; p = .038). Additionally, median TTP was significantly higher in patients treated with MT (p = .010). In patients with non-surgical IMC, the clinical benefit (CB) was reached in 100% (n = 3) of patients receiving MT and in 33% (n = 1) of those receiving ST; the response duration was significantly longer in MT cases (p = .026). The absence of disease progression at day 30 of treatment was significantly associated with longer OST, DFS and TTP (p = .018, p = .002 and p < .001, respectively). Adverse events occurred more frequently in patients treated with MT compared with ST (p = .026). The MT protocol produced primarily mild to moderate toxicities, which were resolved with supportive care; therefore, the combination of drugs was adequately tolerated by most of the patients. The combination of toceranib, a COX-2 inhibitor and oral cyclophosphamide may be a protocol with potential therapeutic efficacy for dogs with IMC.